Previous 10 | Next 10 |
Dexcom CGM use is proven to improve glycemic control 1,2 and can reduce the risk of costly diabetes-related complications compared to fingerstick monitoring. 3 Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM), an...
DexCom One and G7 can prove to be a solid growth catalysts for this leading CGM player. DexCom has also secured FDA approval for two key software solutions, which can further help the company integrate its data more effectively with connected electronic devices and third-party health ...
Shares of Insulet (NASDAQ: PODD) , a medical device company, are jumping in response to regulatory approval of a new product . Investors excited about the company's new automated insulin delivery system pushed the stock 15% higher as of 11:57 a.m. ET on Friday. Today the com...
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2021 financial results after market close on Thursday, February 10, 2022. Management will hold a conference call to review the company's fourth quarter and full year 2021 performance...
Growth stocks, particularly those that thrived at the peak of the coronavirus pandemic, largely fell out of style in 2021. But for many of these companies, that merely amounts to a minor inconvenience in the grand scheme of things. As long as a company's investment thesis remains intact...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Irhythm Technologies (NASDAQ: IRTC ) stock is rising higher Monday alongside heavy trading of the shares. Source: ESB Professional/Shutterstock.com Let’s dive into that news, as well as what else trader...
DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2021 to be approximately $698 million, an increase of 23% over the fourth...
DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 40 th annual J.P. Morgan Healthcare Conference on January 10, 2022. The live presentation, which will occur virtually, i...
Medical device company DexCom (DXCM) garnered investors' attention over the past year due to its advancement in its continuous glucose monitoring (CGM) technology and coverage expansion. However, the growing competition in the diabetes management space is driving down DXCM’s shares. Mo...
Interesting insights can be made while looking at broader market performance comparisons. As major trends are slow to change, these insights can be used to find returns into early 2022 and beyond. While some strong points can be made using the data, factors for each individual hol...
News, Short Squeeze, Breakout and More Instantly...
2024-07-04 10:00:00 ET Growth-oriented investors have experienced a bit of a roller-coaster ride over the past few years. Many companies in the "growth stock" category were struggling just two years ago, but in the bull market we are now experiencing, they're delivering very different resul...
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call to review the company's second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the...